Improving your path to and through the clinic with a regulatory and commercially proven expression platform. Licensing opportunities available for preclinical and clinically developed therapeutics.
Are you seeking to improve the production, economics, and overall derisking the development of your therapeutics?
We ask you to leverage our PET platform capabilities with us, that includes rapid candidate selection, high success rates for expressing challenging molecules, and a reduced time-to-clinic for a wide range of complex modalities. With more than 60 world-wide collaborations with pharmaceutical organizations over the last twenty years, our deep institutional knowledge and unmatched capabilities bring significant value to your product development program. Consider Pelican your experienced partner in expression optimization and the CMC arm for your organization as you prepare for entering the clinic and beyond.
In pursuit of our vision, we have also created a portfolio of therapeutics, produced by our patented Pelican Expression Technology™ platform, many of which include biosimilars and biobetters. Many of these candidates have been developed through Phase I clinical trials and are available for license.
Please contact firstname.lastname@example.org to request more information to engage Pelican as your trusted drug development partner.
Pelican has granted Alvogen the exclusive rights to commercialize and manufacture Pelican’s lead drug candidate, Teriparatide Injection (previously referred to as PF708 and Bonsity), which is being developed as a therapeutic equivalent candidate to Eli Lilly & Company’s Forteo®/Forsteo®, in the United States, the European Union, certain countries in the Middle East and North Africa and the Rest of World territories outside of the countries licensed to Kangchen including, Hong Kong, Mainland China, Malaysia, Singapore and Thailand. Teriparatide Injection (PF708) was developed via the 505(b)(2) regulatory pathway in the United States, and was FDA approved on October 4, 2019 and commercially launched in the US on June 11, 2020. Approval and launch followed in the EU and is ongoing in additional territories.
Alvogen is a global, privately owned pharmaceutical company focused on developing, manufacturing and selling generic, brand, over-the counter (OTC) and biosimilar products for patients around the world. With commercial footprint in over 35 countries, Alvogen’s key regions include the U.S. and emerging markets in the CEE and APAC regions.
Pelican has granted Beijing Kangchen Biological Technology Co. Ltd. (Kangchen), a joint venture between Beijing Konruns Pharmaceutical Co. Ltd. and NT Pharma International Company Limited the exclusive rights to commercialize Pelican’s lead drug candidate, Teriparatide Injection (PF708) which is being developed as a therapeutic equivalent candidate to Eli Lilly & Company’s Forteo®/Forsteo®, in Hong Kong, Mainland China, Malaysia, Singapore and Thailand.
In July 2021 Jazz launched Rylaze™(asparaginase erwinia chrysanthemi (recombinant)-rywn), previously referred to as JZP458 which was developed using Ligand’s Pelican Expression Technology™ platform. Rylaze, is a recombinant erwinia asparaginase used as a component of a multi-agent chemotherapeutic regimen for the treatment of ALL or LBL in adult and pediatric patients one month or older who have developed hypersensitivity to E. coli-derived asparaginase. Additionally, Jazz is utilizing the Pelican Expression Technology™ platform for the development of PF745 (JZP341), a long-acting Erwinia asparaginase for the treatment of acute lymphoblastic leukemia and other hematological malignancies. Jazz has worldwide rights to develop and commercialize PF745.
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases—often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines and novel product candidates, from early- to late-stage development, in neuroscience and oncology.
Merck & Co., Inc. currently has a license agreement for the use of Pelican Expression Technology™ to produce the carrier protein CRM197 for use in conjugate vaccines they are developing. Merck is currently utilizing Pelican expressed CRM197 in their 15-valent Pneumococcal vaccine, V114, plus additional vaccine development programs.
For more than a century, Merck, a leading global biopharmaceutical company known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases.
Serum Institute of India Private Limited (SIIPL) currently has a license agreement for the use of Pelican Expression Technology™ to produce the carrier protein CRM197 for use in conjugate vaccines they are developing. SIIPL is currently utilizing Pelican expressed CRM197 in Pneumosil®, a 10-valent Pneumococcal vaccine, that achieved WHO Prequalification in December 2019. SIIPL is also developing a thermostable Pentavalent Meningococcal Conjugate Vaccine (A, C, Y, W-135, X) that is currently being evaluated in a Phase 3 clinical study plus additional vaccine development programs. In addition, SIIPL is Pelican’s exclusive supplier of pre-clinical grade and cGMP grade CRM197 which Pelican sells to vaccine developers globally, see www.CRM197.com for more information.
Serum Institute of India Pvt. Ltd. is the world’s largest vaccine manufacturer by number of doses produced and sold globally (more than 1.3 billion doses) which includes Polio vaccine as well as Diphtheria, Tetanus, Pertussis, Hib, BCG, r-Hepatitis B, Measles, Mumps and Rubella vaccines. Vaccines manufactured by SIIPL are accredited by the World Health Organization, Geneva and are being used in around 140 countries across the globe in their national immunization programs, saving millions of lives throughout the world.